Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery ...

Find the latest Silexion Therapeutics Corp (SLXN) stock quote, history, news and other vital information to help you with your stock trading and investing.

As May began, Repare Therapeutics announced an out-licensing agreement with the Canadian biotechnology firm DCx Biotherapeutics, involving certain discovery platforms and intellectual property/IP.

Nektar Therapeutics said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin on Tuesday. Shares climbed 27% to $12.15 in after-hours trading Monday ...

Neurodegenerative diseases have always posed a significant therapeutic challenge due to the restrictive nature of the blood–brain barrier (BBB). Intranasal drug delivery has emerged as a noninvasive ...

Candid Therapeutics is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune and inflammatory diseases through novel T-cell engager (TCE) platforms.

CRISPR Therapeutics ’ CRSP first marketed product is the one-shot gene therapy Casgevy, approved in late 2023 and early 2024 across the United States and Europe for two blood disorder ...

PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative ...

Get the latest Silexion Therapeutics Corp (SLXNW) stock news and headlines to help you in your trading and investment decisions.